Your browser doesn't support javascript.
loading
Protein-truncating variants in BSN are associated with severe adult-onset obesity, type 2 diabetes and fatty liver disease.
Zhao, Yajie; Chukanova, Maria; Kentistou, Katherine A; Fairhurst-Hunter, Zammy; Siegert, Anna Maria; Jia, Raina Y; Dowsett, Georgina K C; Gardner, Eugene J; Lawler, Katherine; Day, Felix R; Kaisinger, Lena R; Tung, Yi-Chun Loraine; Lam, Brian Yee Hong; Chen, Hsiao-Jou Cortina; Wang, Quanli; Berumen-Campos, Jaime; Kuri-Morales, Pablo; Tapia-Conyer, Roberto; Alegre-Diaz, Jesus; Barroso, Inês; Emberson, Jonathan; Torres, Jason M; Collins, Rory; Saleheen, Danish; Smith, Katherine R; Paul, Dirk S; Merkle, Florian; Farooqi, I Sadaf; Wareham, Nick J; Petrovski, Slavé; O'Rahilly, Stephen; Ong, Ken K; Yeo, Giles S H; Perry, John R B.
Afiliação
  • Zhao Y; MRC Epidemiology Unit and NIHR Cambridge Biomedical Research Centre, Wellcome-MRC Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge, UK.
  • Chukanova M; Metabolic Research Laboratories, MRC Metabolic Diseases Unit and NIHR Cambridge Biomedical Research Centre, Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge, UK.
  • Kentistou KA; MRC Epidemiology Unit and NIHR Cambridge Biomedical Research Centre, Wellcome-MRC Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge, UK.
  • Fairhurst-Hunter Z; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Siegert AM; Metabolic Research Laboratories, MRC Metabolic Diseases Unit and NIHR Cambridge Biomedical Research Centre, Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge, UK.
  • Jia RY; MRC Epidemiology Unit and NIHR Cambridge Biomedical Research Centre, Wellcome-MRC Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge, UK.
  • Dowsett GKC; Metabolic Research Laboratories, MRC Metabolic Diseases Unit and NIHR Cambridge Biomedical Research Centre, Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge, UK.
  • Gardner EJ; MRC Epidemiology Unit and NIHR Cambridge Biomedical Research Centre, Wellcome-MRC Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge, UK.
  • Lawler K; Metabolic Research Laboratories, MRC Metabolic Diseases Unit and NIHR Cambridge Biomedical Research Centre, Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge, UK.
  • Day FR; MRC Epidemiology Unit and NIHR Cambridge Biomedical Research Centre, Wellcome-MRC Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge, UK.
  • Kaisinger LR; MRC Epidemiology Unit and NIHR Cambridge Biomedical Research Centre, Wellcome-MRC Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge, UK.
  • Tung YL; Metabolic Research Laboratories, MRC Metabolic Diseases Unit and NIHR Cambridge Biomedical Research Centre, Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge, UK.
  • Lam BYH; Metabolic Research Laboratories, MRC Metabolic Diseases Unit and NIHR Cambridge Biomedical Research Centre, Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge, UK.
  • Chen HC; Metabolic Research Laboratories, MRC Metabolic Diseases Unit and NIHR Cambridge Biomedical Research Centre, Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge, UK.
  • Wang Q; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Berumen-Campos J; Experimental Medicine Research Unit, Faculty of Medicine, National Autonomous University of Mexico, Copilco Universidad, Mexico City, Mexico.
  • Kuri-Morales P; Experimental Medicine Research Unit, Faculty of Medicine, National Autonomous University of Mexico, Copilco Universidad, Mexico City, Mexico.
  • Tapia-Conyer R; Instituto Tecnológico de Estudios Superiores de Monterrey, Tecnológico, Monterrey, Mexico.
  • Alegre-Diaz J; Experimental Medicine Research Unit, Faculty of Medicine, National Autonomous University of Mexico, Copilco Universidad, Mexico City, Mexico.
  • Barroso I; Experimental Medicine Research Unit, Faculty of Medicine, National Autonomous University of Mexico, Copilco Universidad, Mexico City, Mexico.
  • Emberson J; Exeter Centre of Excellence for Diabetes Research (EXCEED), University of Exeter Medical School, Exeter, UK.
  • Torres JM; MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
  • Collins R; Clinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
  • Saleheen D; MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
  • Smith KR; Clinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
  • Paul DS; Clinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
  • Merkle F; Center for Non-Communicable Diseases, Karachi, Pakistan.
  • Farooqi IS; Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
  • Wareham NJ; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Petrovski S; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • O'Rahilly S; Institute of Metabolic Science and Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.
  • Ong KK; Metabolic Research Laboratories, MRC Metabolic Diseases Unit and NIHR Cambridge Biomedical Research Centre, Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge, UK.
  • Yeo GSH; MRC Epidemiology Unit and NIHR Cambridge Biomedical Research Centre, Wellcome-MRC Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge, UK.
  • Perry JRB; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Nat Genet ; 56(4): 579-584, 2024 Apr.
Article em En | MEDLINE | ID: mdl-38575728
ABSTRACT
Obesity is a major risk factor for many common diseases and has a substantial heritable component. To identify new genetic determinants, we performed exome-sequence analyses for adult body mass index (BMI) in up to 587,027 individuals. We identified rare loss-of-function variants in two genes (BSN and APBA1) with effects substantially larger than those of well-established obesity genes such as MC4R. In contrast to most other obesity-related genes, rare variants in BSN and APBA1 were not associated with normal variation in childhood adiposity. Furthermore, BSN protein-truncating variants (PTVs) magnified the influence of common genetic variants associated with BMI, with a common variant polygenic score exhibiting an effect twice as large in BSN PTV carriers than in noncarriers. Finally, we explored the plasma proteomic signatures of BSN PTV carriers as well as the functional consequences of BSN deletion in human induced pluripotent stem cell-derived hypothalamic neurons. Collectively, our findings implicate degenerative processes in synaptic function in the etiology of adult-onset obesity.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Células-Tronco Pluripotentes Induzidas / Hepatopatias / Proteínas do Tecido Nervoso Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Células-Tronco Pluripotentes Induzidas / Hepatopatias / Proteínas do Tecido Nervoso Idioma: En Ano de publicação: 2024 Tipo de documento: Article